688 Review Article Epigenetic regulation in bladder cancer: development of new prognostic targets and therapeutic implications Kyoung-Hwa Lee1, Chang Geun Song2 1Department of Urology, Seoul National University Hospital, Seoul, Republic of Korea; 2Department of Safety Engineering, Incheon National University, Incheon, Republic of Korea Contributions: (I) Conception and design: KH Lee; (II) Administrative support: None; (III) Provision of study materials or patients: None; (IV) Collection and assembly of data: KH Lee; (V) Data analysis and interpretation: CG Song; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors. Correspondence to: Kyoung-Hwa Lee, PhD. Department of Urology, Seoul National University Hospital, 101 DaeHakRo, Jongro-Gu, Seoul 02080, Republic of Korea. Email:
[email protected]; Chang Geun Song, PhD. Department of Safety Engineering, Incheon National University, 119 Academy-ro, Yeonsu-gu, Incheon 22012, Republic of Korea. Email:
[email protected]. Abstract: Epigenetic and genetic alterations contribute to cancer initiation and progression. Epigenetics refers to heritable alterations in gene expression without DNA sequence changes. Epigenetic changes include reversible alterations in DNA methylation, chromatin modification, nucleosome positioning, and non-coding RNA profiles. In bladder cancer, many epigenetic changes have been reported to exhibit correlation with cancer progression and malignances. In particular, both DNA hypermethylation and hypomethylation have been reported to be associated with higher bladder cancer rates or advanced tumor stages. The association of changes in histone modifying enzyme expression with bladder cancer stages has been extensively studied. MicroRNA (miRNA) expression also has been studied in bladder cancer diagnosis and disease progression. The use of epigenetics for the diagnosis of and therapeutic target screening in bladder cancer is an emerging and rapidly evolving field.